Jci_page_head_homepage_01 Jci_page_head_homepage_02
Ildikó Toma, Jung Julie Kang, Arnold Sipos, Sarah Vargas, Eric Bansal, Fiona Hanner, Elliott Meer, János Peti-Peterdi
Published in Volume 118, Issue 7
J Clin Invest. 2008; 118(7):2526–2534 doi:10.1172/JCI33293
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 2
Effects of TCA cycle intermediates and inhibitors on renin release.

(A) Overview of the TCA cycle and sites of inhibition with fluorocitrate (F; 100 μM; blocks aconitase in step 2) and malonate (MAL; 1 mM; blocks succinate dehydrogenase in step 6). (B) Effects of TCA cycle inhibitors on renin release in presence of normal (5.5 mM when not indicated) or high glucose (25.5 mM), or succinate (SUCC, 5 mM) levels. C, control. *P < 0.001, control vs. high glucose, high glucose plus succinate, succinate, and malonate. **P < 0.001 malonate alone vs. malonate plus high glucose, and malonate plus succinate. n = 6 each. (C) Dose-dependent effects of succinate and malonate on in vitro renin release. n = 6 measurements for each dose. (D) Representative recordings of changes in quinacrine fluorescence intensity (renin release) in control and in response to high glucose and succinate levels (black lines), and the time course of the high glucose level–induced afferent arteriole vasodilatation (gray line).